Adial pharmaceuticals announces research collaboration with the medical college of wisconsin to advance purnovate's adenosine compounds as potential treatments for diabetes and nash

Charlottesville, va., may 19, 2022 (globe newswire) -- adial pharmaceuticals, inc. (nasdaq: adil; adilw) (“adial” or the “company”), today announced that purnovate, inc., an adial company focused on developing novel molecules targeting the adenosine receptors for the treatment of major unmet medical needs, has entered into a research collaboration with the medical college of wisconsin, a leading medical school, and dr. john auchampach, phd, professor and vice chair of the department of pharmacology and toxicology. the goal of the collaboration is to further evaluate the company's proprietary adenosine analogs as potential treatments for diabetes and non-alcoholic steatohepatitis (nash). nash is the most severe form of non-alcoholic fatty liver disease involving liver inflammation (hepatitis) that can lead to life-threatening cardiovascular co-morbidities.
ADIL Ratings Summary
ADIL Quant Ranking